CCS
TCRT icon

Crosspoint Capital Strategies’s Alaunos Therapeutics TCRT Stock Holding History

Crosspoint Capital Strategies’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-33
Closed -$41K – 729
2015
Q4 		$41K Sell
33
-4
-11% -$6.62K 0.01% 471
2015
Q3 		$51K Sell
37
-3,957
-99% -$6.53M 0.06% 251
2015
Q2 		$7.19M Buy
3,994
+1,705
+74% +$2.65M 2.04% 6
2015
Q1 		$3.7M Buy
+2,289
New +$3.39M 1.78% 10

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Crosspoint Capital Strategies's TCRT Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Alaunos Therapeutics (TCRT) in Q1 2016, closing a stake of 33 shares — an estimated $41K sold.

Crosspoint Capital Strategies first reported a position in TCRT in Q1 2015 and held it in 4 quarters. The position peaked at $7.19M in Q2 2015. 143 funds tracked by Wall St. Rank hold TCRT as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Alaunos Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 33 Alaunos Therapeutics shares in Q1 2016, an estimated $41K.
  • Crosspoint Capital Strategies first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 4 quarters.
  • Crosspoint Capital Strategies's Alaunos Therapeutics position peaked at $7.19M in Q2 2015.
  • 143 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.